eases. Furthermore, the challenge of multiple concomitant pathologies while on MPA treatment, in particular infectious diseases, is discussed, and some open questions concerning the effects of MPA on colon pathology are pointed out.
Introduction
Diarrhea is a clinical symptom reflecting abnormalities in the gastrointestinal tract of a variety of different diseases. Diarrhea developing in immunocompromised individuals differs from diarrhea developing in immunocompetent individuals with respect to the spectrum of underlying causes, pathophysiological mechanisms, clinical presentation and histopathological findings. Integrity of the intestinal mucosa is one of the many factors required for a normal bowel function. The intestinal epithelial layer at the mucosal surface has a barrier function which is crucial for mucosal integrity. The intestinal epithelium is a dynamic compartment and is subject to permanent turnover and regeneration in case of injury. Intestinal epithelial cells (EC) have a high turnover rate and are estimated to be replaced every 3-5 days. Besides physiological shedding of intestinal EC into the bowel lumen, intestinal EC may be lost as the result of damage to the epithelium. A morphological correlate of such damage is the occurrence of apoptosis in intestinal EC.
Materials and Methods
For this study, cases of likely or possible mycophenolate (mycophenolic acid, MPA) colonopathy were retrospectively identified from the files of the Institute of Surgical Pathology, University Hospital Zurich, for the period 2009-2012. Clinical information on patient history, clinical presentation and endoscopic findings were recorded, when available, from clinical information. All cases were routinely processed, i.e. stained by hematoxylin and eosin (HE) stain, optionally supplemented by special histochemical and immune stains for suspected infectious agents. Overall, we identified 18 cases of likely or possible MPA colonopathy in 16 different patients (rebiopsies in 2 cases; see table 1 ). The study was in line with the local ethical regulations (Reglement für den Zugriff auf Patientendaten zu Forschungszwecken; University Hospital Zurich).
Apoptosis in Normal Colonic Mucosa and Bowel Preparation Effects
As it takes more than one swallow to make a summer, it takes more than one colonic apoptosis to make a colonic pathology. A single apoptotic intestinal EC in an otherwise unremarkable colonic mucosa is not abnormal per se. In early studies performed to quantify how many apoptoses can be found in a nondiseased colonic mucosa, a threshold of 5 apoptotic bodies per 100 crypts found in an HE-stained slide has been determined [1] . When evaluating colonic biopsies, one has to be aware of histological changes resulting from the bowel preparation procedure; this includes scattered apoptosis of colonic EC [2] . For practical purposes, the finding of more than an occasional apoptotic colonic EC should be regarded as abnormal and prompt a search for an underlying condition. The histological finding of a pathologically increased number of apoptoses in the colon mucosa is coined with the generic term apoptotic colonopathy.
MPA-Induced Colonopathy
In recent years, we increasingly observed colonic biopsies taken for the clinical workup of diarrhea that revealed (among others) the finding of apoptotic colonopathy which was ultimately related to the use of the immunosuppressive drug MPA. This observation in our practice was paralleled by a growing body of literature on MPA- 284 related histopathological findings [3] [4] [5] [6] . MPA is an inhibitor of inosine-5 ′ -monophosphate dehydrogenase and blocks the de novo purine synthesis required for DNA synthesis and cell division. MPA and its prodrug mycophenolate mofetil (MMF) have several immunosuppressant actions and prevent allograft rejection by several mechanisms: proliferation of T and B lymphocytes is inhibited and cell-mediated immune responses and antibody formation are suppressed, dendritic cell maturation impaired and anti-inflammatory activity further impaired by the inhibition of interleukin (IL-1) expression together with the enhanced expression of the IL-1 receptor antagonist [7] . MPA is frequently used to prevent rejection in (solid) organ transplantations, and is available either as the prodrug MMF (CellCept ® , Roche
Pharma AG, Reinach, Switzerland) or the salt mycophenolate sodium (Myfortic ® , Novartis Pharma AG, Stein, Switzerland), differing mostly with respect to a more gastric or enteric absorption, respectively [8] .
Among other adverse effects, MPA may also cause damage to the gastrointestinal tract [9] . Typical clinical presentations of MPA-related gastrointestinal toxicity include afebrile, watery diarrhea with mostly unremarkable or mild endoscopy findings. The entire gastrointestinal tract including the upper part can be affected by MPA toxicity [3] , and macroscopic features may include ulcers and erosions throughout the entire gut. The epithelial or glandular compartment is the main target of MPA-related toxicity. The predominant patterns of injury are an acute inflammatory pattern and/or an apoptotic pattern. Major histopathological findings comprise a picture resembling self-limited colitis, an inflammatory bowel disease (IBD)-like picture and a graft-versus-host disease (GvHD)-like picture [4, 6, 10] . Typical histological features include a (mostly mild) crypt architectural disarray, colonic crypt atrophy and dropout which may result in an IBD-like pattern over time ( fig. 1 a, left) , a paucity of inflammatory cells in the lamina propria ('empty lamina propria appearance'), atrophy of the epithelial lining cells with typical dilated crypts containing an attenuated epithelial lining and cellular debris in their lumen ( fig. 1 a,  middle) and a notably increased number of crypt cell apoptoses ( fig. 1 a, right) . As illustrated in figure 1 a, the different histopathological key findings are best evaluated on low-power view (architecture, left), medium-power view (epithelial changes, middle) and high-power view (apoptosis, right), respectively. Whereas none of the above-mentioned findings is specific for MPA, the simultaneous observation of a mixed pattern of injury (architectural distortion, increased number of crypt cell apoptosis, epithelial changes with cystically dilated crypts) is characteristic for MPA toxicity [6, [10] [11] [12] . Variably encountered additional findings are an increased number of eosinophils in the lamina propria and a (relatively) increased number of neuroendocrine cells which seem to be less prone to undergo apoptosis.
In contrast to the early years of MPA use, with an increased awareness of MPA toxicity deriving from clinical sites, information on MPA treatment is nowadays frequently given. The above-listed histopathological findings -especially when a combination of the several patterns is found -are so characteristic of MPA toxicity that this must be mentioned with the differential diagnoses in the pathology report, even when corresponding clinical information is lacking. In our experience, in such cases, communication with clinical partners regarding specific questions on MPA treatment can be helpful, in many instances leading to the diagnosis.
Differential Diagnoses
Unfortunately, even when the full spectrum of changes listed is present, the above-listed histopathological findings are not restricted to cases of MPA toxicity. The most relevant differential diagnoses are listed in table 2 with respect to features useful for differential diagnostic considerations. As outlined, MPA toxicity can present with histological pictures resembling self-limited infectious colitis, IBD and/or GvHD, respectively; these are thus obviously among the differential diagnoses. In daily practice, IBD is not a major differential diagnosis, as medical history, clinical presentation and endoscopic findings of IBD patients are mostly different from patients with MPA colonopathy. Histopathologically, MPA colonopathy and IBD may both have architectural disarray. However, IBD typically has an increased inflammatory infiltrate in the lamina propria which is in contrast to the paucicellular ('empty-appearing') lamina propria in MPA colonopathy. Furthermore, IBD cases tend to have more features of chronicity, and metaplasia (mucinous or pyloric-gland type) or granulomas can be found which are typically not seen in MPA colonopathy.
In contrast, infectious colitis is a relevant differential diagnosis. Increased apoptosis of the crypt epithelium is a feature of infections caused by a variety of agents including bacterial infections, especially the toxin-producing ones, and in particular viral infections caused by human cytomegalovirus (CMV) and adenovirus, but also protozoal infections, especially Cryptosporidium . Patients un- der immunosuppression, including that resulting from MPA treatment, are naturally at a higher risk for developing opportunistic infections. Consequently, even in cases with features suggesting MPA-related changes like increased apoptosis of the crypt epithelium, the presence of concomitant infections must be determined, and a low threshold for further workup including more levels, specific and immune stains should be given.
GvHD [13] is probably the condition which shares the most histopathological features with MPA-related colonopathy to a degree that a GvHD-like pattern is regarded as a characteristic feature of MPA-related colonopathy. Both conditions reveal a predominantly inflammatory injury pattern affecting the epithelial compartment.
Apoptosis of the crypt epithelium is a hallmark of both as well as a paucity of lamina propria inflammatory cells. GvHD may progress to a condition with marked crypt distortion resembling IBD, similar to how MPA-related colonopathy does. Although on the one hand, MPA-related colonopathy often shows cystically dilated crypts ( fig. 1 a, middle panel) which GvHD usually does not, and on the other hand, GvHD can have a partially or totally denuded mucosa ( fig. 1 a) which is not a typical MPA effect, both conditions may, in fact, look identical and can thus not be distinguished from each other purely on the basis of histology. Taking into account the clinical setting, with a history of hematopoietic cell transplantation (in rare cases, solid organ transplantation) and a clinical pre- sentation of skin and liver affection, usually gives direction to the diagnosis of GvHD. However, if patients in the right setting for GvHD also have a history of MPA treatment, a distinction based purely on histology might be impossible and so has to be made clinically.
Other conditions with impaired or modulated immune response which have apoptotic colonopathy as a histopathological feature are autoimmune enterocolitis, common variable immunodeficiency and AIDS-related colonopathy ( fig. 1 c, usually observed only in patients with very low T cell counts, nowadays rarely observed in resource-rich countries due to the implementation of combination antiretroviral therapy to decrease HIV replication and restore immune status). Usually, the clinical setting is different and is known, thus rarely implicating these conditions as differential diagnoses to MPA effects. Moreover, specific or characteristic histopathological findings pointing to the underlying disease are a decreased count of mucosal plasma cells in common variable immunodeficiency [14] and a lack of goblet cells or Paneth cells in autoimmune enterocolitis [15] . Drugs, other than bowel preparations and MPA, which have been reported to lead to increased epithelial apoptosis are nonsteroidal anti-inflammatory drugs, anthraquinone laxatives [16] and chemotherapeutic agents, especially 5-FU [1, 5] .
MPA-Induced Colonopathy with Multiple Pathologies
Patients taking immunosuppressive drugs are at higher risk to develop (opportunistic) infections. After hematopoietic cell transplantation, patients are at risk for GvHD. Therefore, patients on MPA treatment per se who develop diarrhea likely have a higher probability of having more than one of the above-discussed conditions. We have observed several cases in which patients on MPA treatment revealed dual or even multiple pathologies. The case of a 53-year-old female, who developed diarrhea while on MPA treatment for renal transplantation, illustrates such a scenario ( fig. 1 d-g ). Besides histological findings consistent with MPA effects like mild architectural disarray ( fig. 1 d) and an increased number of crypt apoptosis, a low-power view showed areas with distinct findings already suggesting additional pathologies. A high-power view then revealed the presence of tapeworm scolices at multiple sites of the mucosa ( fig. 1 d, inset 1 ) which were identified as the dwarf tapeworm (Hymenolepis nana) . Other areas revealed active colitis with erosions, cystically dilated crypts and multiple EC with both nuclear and cytoplasmic inclusions ( fig. 1 d, inset 2) leading to the diagnosis of CMV infection. In line with our observations, in a recently published study on MPA-associated colitis, Lee et al. [11] describe dual pathology in 3 of 7 cases, 2 of which were with concomitant CMV infection. Their findings and our own observations support the notion that patients on MPA treatment do indeed have a higher risk of developing dual or multiple pathologies. Therefore, when evaluating the colonic biopsies of such patients, pathologists must be aware that the histological picture of MPA effects overlaps with that of other conditions. This calls for an active and thorough search for additional diagnoses beyond these effects.
MPA-Induced Colonopathy: Perspectives and Unanswered Questions
Despite the growing body of literature in recent years and the fact that clinicians and pathologists nowadays are aware of and familiar with the effects of MPA on the gastrointestinal tract, our knowledge is mostly based on retrospective observational and correlative studies, and several fundamental questions still remain. These include points to be addressed from a basic research as well as a clinicopathological perspective. (1) Do the histopathological findings found in association with MPA treatment [3, 4, 6, 10] correlate with the clinical symptoms, in particular diarrhea? The current concept is based on this assumption, but there are no data on the frequency of MPAtypical histopathological changes in patients not suffering from diarrhea. (2) What are the dynamics of histopathological changes and clinical symptoms in relation to MPA treatment with respect to occurrence, persistence and reversibility? (3) Are there drugs other than MPA which can cause the same spectrum of histopathological changes? We have seen, sporadically, colonic biopsies with histopathological patterns virtually identical to those of the MPA effects in our own practice [unpubl. observation], suggesting that these findings probably reflect a stereotypical final pathway of several insults rather than an MPA-specific pattern. (4) To what extent do MPA effects and IBD share pathophysiological mechanisms? The big question is: Does long-term treatment with MPA come with an increased risk for cancer development going beyond the risk attributable to immunosuppression? This is conceivable, taking into account our own observation that a persistently elevated apoptosis rate may, on its own, cause cancer in tissues with the capacity for repair [17] .
Conclusions
In recent years, MPA treatment has been identified as an underlying cause of apoptotic colonopathy, along with the clinical presentation of diarrhea. Characteristic histopathological findings overlap with infectious colitis, IBD and GvHD. In daily practice, it is important to recognize these features and to consider MPA toxicity, but also to not overlook concomitant pathologies like infectious diseases, to which patients on MPA treatment are prone. There are important questions relating to the effects of MPA on the gastrointestinal tract that remain unanswered. It would be pertinent to address the causal relation and specificity of histopathological findings, the clinical symptoms (in particular, diarrhea) and the question of long-term treatment.
